Edina, Minn. – September 18, 2026 -- ReEmerge, Inc. has closed an oversubscribed $37 million Series A financing and exited stealth mode to advance a novel therapy targeting chronic cognitive impairment caused by traumatic brain injury (TBI).
Investor syndicate backs first-of-its-kind neural stimulation approach
U.S. Venture Partners (USVP) and Santé co-led the round, joined by Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures. The capital will fund an upcoming clinical study, technology development, and expansion of clinical and regulatory operations.
CNRT technology targets the central thalamus to reverse cognitive deficits
ReEmerge's proprietary Cognitive Network Restoration Therapy (CNRT) precisely targets neural networks in the central thalamus, a brain hub involved in attention, arousal, and executive function. Rather than helping patients compensate for lost function, the therapy aims to activate underactive but viable neural circuits to reverse deficits and restore independence.
Technology originates from decades of research at Weill Cornell Medicine, Stanford and Utah
CNRT builds on research led by Nicholas Schiff, M.D., Professor of Neuroscience at the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine, alongside colleagues at Stanford University and the University of Utah, examining brain electrical stimulation after TBI. A pilot study showed patients regaining cognitive function, with findings published in Nature Medicine. The Center for Technology Licensing at Weill Cornell licensed the foundational intellectual property to ReEmerge.
Clinical trial to enroll up to 40 patients with chronic moderate-to-severe TBI
ReEmerge will conduct a prospective, single-arm, multicenter study (NCT07730099) evaluating CNRT in patients with chronic moderate-to-severe TBI, enrolling up to 40 participants and assessing cognitive and functional outcomes.
27 million people globally suffer TBI annually, many with lasting impairment
An estimated 27 million people worldwide experience a traumatic brain injury each year, with many left with persistent cognitive impairment, according to a 2023 BMJ Open study. Current rehabilitation-focused treatment pathways often plateau, leaving patients with lasting deficits that limit independence and quality of life.
"ReEmerge's technology represents a fundamentally different approach to cognitive recovery with the potential to transform the recovery pathway," said Jonathan Root, MD, General Partner at USVP.
Todd Langevin, Chief Executive Officer of ReEmerge, said the company will use the funding to initiate its TBI clinical study and build clinical evidence to support the differentiated therapeutic approach.